I am pretty pleased that BDA is appointing credible management with exceptional networks and experience to steer our BDA ship forward.
I also note that this is appointment is an executive role so will play a key partnership role with our MD and CEO to commercialise our medical cannabis products.
BDA to move to 60c+ holding zone and ready to break and create new highs on a substantial commercial FA update.
The low market capitalisation versus peers and tight capital structure should see us rerate significantly